NASDAQ: TALKTalkspace Inc Stock
$2.49-0.07 (-2.73%)
Updated Sep 16, 2025
TALK Price
$2.49
Fair Value Price
N/A
Market Cap
$416.99M
52 Week Low
$1.88
52 Week High
$4.36
P/E
124.5x
P/B
3.69x
P/S
2.3x
PEG
0.77x
Dividend Yield
N/A
Revenue
$202.61M
Earnings
$2.87M
Gross Margin
44.3%
Operating Margin
-1.09%
Profit Margin
1.4%
Debt to Equity
0.18
Operating Cash Flow
$9M
Beta
0.9
Next Earnings
Oct 27, 2025
Ex-Dividend
N/A
Next Dividend
N/A
TALK Overview
Talkspace Incorporated delivers virtual behavior healthcare through a web and mobile platform. Treatment options cover every need including psychiatry, and adolescent, individual, and couples therapy. Therapy is provided by a network of licensed therapists by way of chat/email messages, videos, voice messages, live videoconference sessions. The company was founded 2011 and is headquartered in New York, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TALK's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
B
TALK
Ranked#23 of 43
Ranked#23 of 43
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $20.75 | A | |
| $17.35 | A | |
| $18.12 | B |
Be the first to know about important TALK news, forecast changes, insider trades & much more!
TALK News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TALK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TALK ($2.49) is trading above its intrinsic value of $1.36, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TALK is poor value based on its earnings relative to its share price (124.5x), compared to the US market average (37.55x)
P/E vs Market Valuation
TALK is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more TALK due diligence checks available for Premium users.
Valuation
TALK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
124.5x
Industry
80.94x
Market
37.55x
TALK is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
TALK is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
TALK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.69x
Industry
4.12x
TALK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TALK price to earnings growth (PEG)
For valuing profitable companies with growth potential
TALK is good value based... subscribe to Premium to read more.
PEG Value Valuation
TALK's financial health
Profit margin
Revenue
$54.3M
Net Income
-$541.0k
Profit Margin
-1%
TALK's Earnings (EBIT) of -$2.21M... subscribe to Premium to read more.
Interest Coverage Financials
TALK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$132.8M
Liabilities
$19.8M
Debt to equity
0.18
TALK's short-term assets ($120.67M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TALK's short-term assets ($120.67M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TALK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TALK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$351.0k
Investing
-$2.4M
Financing
-$3.0M
TALK's operating cash flow ($8.70M)... subscribe to Premium to read more.
Debt Coverage Financials
TALK vs Health Information Service Stocks
Talkspace Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.